70.30 <%= Resources.Global.txtDown %>
Updated 17/04/2019
Change % -1.40% Stock price decreasing
Change -1.00 Stock price decreasing
Volume 406,387
High 72.04
Low 70.30
Open 71.42
ISIN BE0003739530
Prev close 71.30
# of shares 194.51M
Market cap 13,674M EUR

Market closed
Market is closed, opens at 08:00
Price development Latest 1 week 1 month 3 months 6 months 1 year
  70.30 -6.7% Stock price decreasing -8.3% Stock price decreasing -7.8% Stock price decreasing -3.6% Stock price decreasing 7.7% Stock price increasing
Powered by TradingView

Company profile

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, both of which have lost patent protection. The firm's newer drugs include Cimzia (rheumatoid arthritis, psoriatic arthritis, and Crohn's disease), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), and Briviact (epilepsy).

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
21 April 2019 21:52:34
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190410.2 - EUROWEB5 - 2019-04-21 22:52:34 - 2019-04-21 21:52:34 - 1000 - Website: OKAY